A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis

Dimitrios Karagiannis, Ilias Georgalas, Ioannis Ladas, Parikakis Eustratios, Panagiotis Mitropoulos

1Second Department of Ophthalmiatrion Eye Hospital, NHS, Athens, Greece; 2Department of Ophthalmology, “G.Genimatas” General Hospital, Athens, Greece

Abstract: A 65-year-old lady presented with decreased vision in her left eye (LE). Best corrected visual acuity (BCVA) was 1/20. Complete examination showed idiopathic juxtafoveal retinal telangiectasis associated with subretinal neovascularization and she was treated with intravitreal ranibizumab every month for three months in the LE. After four months, her BCVA increased to 3/10. Fluorescein angiography (FA) showed minimal leakage and optical coherence tomography (OCT) confirmed absence of intra- or subretinal fluid in the macula. Examinations were repeated monthly for another 12 months and showed no recurrence. Intravitreal ranibizumab showed promising results for subretinal neovascularization due to idiopathic juxtafoveal retinal telangiectasis. A prospective study with large series of patients and controls may be necessary in order to determine the effectiveness of this treatment.

Keywords: idiopathic juxtafoveal retinal telangiectasis, ranibizumab, subretinal neovascularization

Introduction
Gass and Blodi defined bilateral acquired retinal telangiectasis or perifoveal telangiectasia or type 2A telangiectasis as a rare retinal disease characterized by retinal thickening temporal to the fovea, right-angle venules, retinal pigment epithelial (RPE) hyperplastic plaques, and crystalline deposits. Bilateral acquired retinal telangiectasis can be divided into five stages. The disease is usually becoming symptomatic through the sixth decade of life when complicated by subretinal neovascularization which is localized mostly subfoveally in stage 5 of the disease.1–3

We report the outcome of treatment with 0.5 mg intravitreal ranibizumab in a patient with a subretinal neovascular membrane secondary to idiopathic juxtafoveal retinal telangiectasis.

Case history
A 65-year-old Caucasian lady presented to our clinic complaining of decreased vision in her left eye (LE). On presentation, best-corrected visual acuity (BCVA) was 10/10 in the right eye (RE) and 1/20 LE. Anterior segment examination was unremarkable in both eyes and intraocular pressures were within normal limits. Fundus biomicroscopy revealed in the right macula, slightly dilated right-angle veins with RPE hyperplasia beneath them (Figure 1A). In addition to these findings, in the left macula there was subretinal hemorrhage (Figure 1B). The clinical appearance of the macular area of the LE was consistent with idiopathic juxtafoveal retinal telangiectasis complicated by subretinal neovascularization. Fluorescein angiography (FA) and optical coherence tomography (OCT) were performed and confirmed the above diagnosis (Figures 1C–D, 2, 3A). OCT of the LE revealed the characteristic appearance of outer and inner retina having similar reflectivity and an area temporal to the fovea with high
refl ectivity corresponding to the temporal area of choroidal neovascularization (CNV) (Figure 3A), which was observed in the angiogram. After a discussion outlining the possible risks and benefits of the treatment, the patient was started on 0.5 mg intravitreal ranibizumab in the LE. Based on the findings of FA and OCT which were performed monthly, the patient underwent three intravitreal injections of ranibizumab every month for three months. Following these injections, BCVA increased to 3/10 and both clinical and angiographic appearances showed significant improvement with minimal leakage in FA and absence of intra- or subretinal fluid in OCT and significant reduction in retinal thickness; the RPE remained thickened (Figures 3B, 4A–B). Examinations were repeated monthly for another 12 months and showed no recurrence of CNV.

Discussion

Bilateral acquired retinal telangiectasis or retinal telangiectasis type 2A, according to Gass and Blodi, or type 2 perifoveal telangiectasia according to the classification by Yannuzzi is a symmetrical disease.1,3 The area involved is usually less than a disc diameter and is typically temporal to the fovea.4 Gas and Blodi divided the development of group 2A telangiectasis into five stages.1 Stage 1 is found on FA on the asymptomatic fellow eye as staining at the level of the RPE. Stage 2 is characterized by the loss of transparency of the retina near the fovea and visible telangiectasis only in FA. In stage 3, FA shows capillary dilatation and staining. Stage 4 reveals migrating RPE cells appearing as stellate foci along the right-angle venules. Stage 5, according to Gass and Blodi, or the proliferative stage according to...
In our case we chose to use ranibizumab since it appears to be efficacious in the treatment of subretinal neovascularization associated with proliferative type 2 idiopathic macular telangiectasia (Table 1). 10

In conclusion, intravitreal ranibizumab seems to have favorable results in the treatment of subretinal neovascularization due to idiopathic juxtapfoveal retinal telangiectasia. Further studies are required to evaluate the above findings, although the implementation of large-series studies remains a challenge due to the rarity of cases with subretinal neovascularization secondary to idiopathic juxtapfoveal retinal telangiectasia.

Disclosure
The authors report no conflicts of interest in this work.

References

Table 1 Anti-VEGF for the treatment of subretinal neovascular membrane associated with type 2 idiopathic macular telangiectasia: Summarized review of the literature

<table>
<thead>
<tr>
<th>Author et al publication</th>
<th>Patients</th>
<th>Anti-VEGF</th>
<th>PDT</th>
<th>Follow-up (months)</th>
<th>Year of publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rishi et al10</td>
<td>1</td>
<td>Ranibizumab</td>
<td>Yes</td>
<td>16</td>
<td>2008</td>
</tr>
<tr>
<td>Mandal et al7</td>
<td>6</td>
<td>Bevacizumab</td>
<td>No</td>
<td>3–6</td>
<td>2008</td>
</tr>
<tr>
<td>Jorge et al8</td>
<td>1</td>
<td>Bevacizumab</td>
<td>No</td>
<td>24</td>
<td>2008</td>
</tr>
<tr>
<td>Ruys et al6</td>
<td>2</td>
<td>Bevacizumab</td>
<td>Case 1:Yes Case 2:No</td>
<td>1–3</td>
<td>2007</td>
</tr>
<tr>
<td>Moon et al7</td>
<td>1</td>
<td>Bevacizumab</td>
<td>No</td>
<td>3</td>
<td>2007</td>
</tr>
</tbody>
</table>

 Abbreviations: PDT, photodynamic therapy; VEGF, vascular endothelial growth factor.